2 results
Approved WMOCompleted
Primary: Progression Free Survival (PFS) in patients treated with AUY922 versus pemetrexed or docetaxel.Secondary: Overall response rate, disease control rate, overall survival, safety and tolerability, PK.
Approved WMORecruiting
To determine a safe dose combination of carboplatin-cyclophosphamide combined with atezolizumab fixed dose in advanced breast cancer and gynaecologic cancer (ovarian, cervical and endometrial cancer).